Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes. OBJECTIVE: To evaluate the treatment effect of alemtuzumab on low-contrast vision in relapsing–remitting multiple sclerosis (RRMS) patients. METHODS: This was a pre-defined exploratory analysis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Graves, Jennifer, Galetta, Steven L, Palmer, Jeffrey, Margolin, David H, Rizzo, Marco, Bilbruck, John, Balcer, Laura J
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2013
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3807733/
https://ncbi.nlm.nih.gov/pubmed/23459567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458513475722
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados